CoChat
Sign Up
Cited by 678Menopause: Health Impacts and TreatmentsEstrogen and related hormone effectsBreast Cancer Treatment Studies

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial

Open access
Cauley, Jane A., Norton, Larry, Lippman, Marc E., Eckert, Stephen, Krueger, Kathryn A., Purdie, David W., Farrerons, Jordi, Karasik, Avraham, Mellstrom, Dan, Ng, Kong Wah, Stepan, Jan J., Powles, Trevor J., Morrow, Monica, Costa, Alberto, Silfen, Sheryl L., Walls, Erin L., Schmitt, Henry, Muchmore, Douglas B., Jordan, V. Craig·2001·Breast Cancer Research and Treatment
DOI 10.1023/a:1006478317173
Open this paper in CoChat — free account

Abstract

Raloxifene, a selective estrogen receptor modulator approved for the prevention and treatment of postmenopausal osteoporosis, has shown a significant reduction in breast cancer incidence after 3 years in this placebo-controlled, randomized clinical trial in postmenopausal women with osteoporosis. This article includes results from an additional annual mammogram at 4 years and represents 3,004 additional patient-years of follow-up in this trial. Breast cancers were ascertained through annual screening mammograms and adjudicated by an independent oncology review board. A total of 7,705 women were enrolled in the 4-year trial; 2,576 received placebo, 2,557 raloxifene 60 mg/day, and 2,572 raloxifene 120 mg/day. Women were a mean of 66.5-years old at trial entry, 19 years postmenopause, and osteoporotic (low bone mineral density and/or prevalent vertebral fractures). As of 1 November 1999, 61 invasive breast cancers had been reported and were confirmed by the adjudication board, resulting in a 72% risk reduction with raloxifene (relative risk (RR) 0.28, 95% confidence interval (CI) 0.17, 0.46). These data indicate that 93 osteoporotic women would need to be treated with raloxifene for 4 years to prevent one case of invasive breast cancer. Raloxifene reduced the risk of estrogen receptor-positive invasive breast cancer by 84% (RR 0.16, 95% CI 0.09, 0.30). Raloxifene was generally safe and well-tolerated, however, thromboembolic disease occurred more frequently with raloxifene compa…

Overview

Integrity signals

Registry

Crossref · 10.1023/a:1006478317173

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Raloxifene is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis.

    “Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”

    From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [83]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 4

  1. Cohen FJ, Watts S, Shah A, Akers R, Plouffe L: Uterine effects of three-year raloxifene therapy in postmenopausal women under age 60. Obstet Gynecol 95: 104-110, 2000
  2. National Institutes of Health, Office of Cancer Communications: Publication of the MORE Trial Results Support Study of Tamoxifen and Raloxifene (STAR). Press Release of National Cancer Institute, 1999
  3. Freedman M, San Martin J, O'Gorman J, Eckert S, Lippman ME, Lo S-C, Walls EL, Zeng J: Digitized mammography: A clinical trial of post menopausal women randomized to raloxifene, estrogen, or placebo, J Natl Cancer Inst, (In press)
  4. Ries LAG, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK (eds): SEER Cancer Statistics Review, 1973-1996. National Cancer Institute, Bethesda, MD, 1999

Cited by

Sorted by citations

Related

Metadata

Authors
Cauley, J. A., Norton, L., Lippman, M. E., Eckert, S., Krueger, K. A., Purdie, D. W., Farrerons, J., Karasik, A., Mellstrom, D., Ng, K. W., Stepan, J. J., Powles, T. J., Morrow, M., Costa, A., Silfen, S. L., Walls, E. L., Schmitt, H., Muchmore, D. B., & Jordan, V. C.
Affiliations
  • University of Pittsburgh (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Georgetown University (US)
  • Eli Lilly (United States) (US)
  • University of Hull (GB)
  • Sheba Medical Center (IL)
  • The University of Melbourne (AU)
  • Charles University (CZ)
  • Royal Marsden NHS Foundation Trust (GB)
  • Northwestern University (US)
  • European Institute of Oncology (IT)
ORCID
Venue
Breast Cancer Research and Treatment
Publisher
Springer Science and Business Media LLC
Published
2001-01
Volume
65
Issue
2
Pages
125-134
ISSN
  • 0167-6806 (ISSN-L)
  • 1573-7217
DOI
10.1023/a:1006478317173
OpenAlex
W1986364825
Cited by
678
References
28
Citations by year
2026: 1 · 2025: 11 · 2024: 5 · 2023: 7 · 2022: 11 · 2021: 8 · 2020: 15 · 2019: 13 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 22 · 2014: 21 · 2013: 21 · 2012: 20
FWCI
46.50
Type
journal article
Language
en
Open access
Licence
Locations
  • Breast Cancer Research and Treatment (publishedVersion)
  • PubMed (publishedVersion)
  • University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
  • Padua Research Archive (University of Padova) (submittedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
raloxifene, selective estrogen receptor modulators, breast cancer prevention, postmenopausal women, osteoporosis, MORE trial, estrogen receptor-positive breast cancer, thromboembolic events, long-term follow-up
MeSH terms
Aged, Aged, 80 and over, Australia, Breast Neoplasms, Double-Blind Method, Estrogen Antagonists, Europe, Female, Follow-Up Studies, Humans, Mammography, Middle Aged, New Zealand, Risk Factors, United States, Osteoporosis, Postmenopausal, Incidence, Ultrasonography, Mammary, Postmenopause, Selective Estrogen Receptor Modulators, Raloxifene Hydrochloride

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review